News

Filter

Current filters:

Rebetol

1 to 9 of 315 results

Stock Commentary - New York week to April 27, 2009

30-04-2009

NEW YORK: equities moved up and down during the reporting period to April 27, regaining, and holding…

AmgenCopegusMerck KGaAPegasysPeginterferon alfa-2aRebetolRibavirinRocheVirazole

Debiopharm hails strong results with HCV drug

28-04-2009

Swiss drugmaker Debiopharm has presented results from a Phase IIa study with Debio 025, a selective cyclophilin…

AlphaCopegusProlastinRebetolRibavirinVirazole

Vertex' telaprevir achieves unprecedented SVR

27-04-2009

Vertex' telaprevir achieved the highest sustained viral response rate ever reported for a hepatitis C…

CopegusNystatinOralRebetolRibavirinSchering PloughSchering-PloughVirazole

Anadys shares drop 35% on mixed HCV drug data

24-04-2009

Anadys shares fell 35.5% to $3.80 in afternoon trading on April 21, after the US drug developer presented…

CopegusRebetolRibavirinVirazole

GlobeImmune's Tarmogen plus SOC shows 94% EVR

24-04-2009

12-week Phase II trial data show that patients treated with GI-5005, GlobeImmune's targeted molecular…

CopegusRebetolRibavirinVirazole

S-P's boceprevir reduces SVR after 28 weeks in Ph II study

24-04-2009

US drug major Schering-Plough's boceprevir, its investigational oral hepatitis C protease inhibitor,…

CopegusNystatinOralPeg-IntronPeginterferon alfa-2bRebetolRibavirinSchering PloughSchering-PloughVirazole

PEG-INF lambda reduces HCV RNA with no liver AEs

24-04-2009

US drug major Bristol-Myers Squibb and local partner ZymoGenetics reported data showing that the investigational…

Bristol-Myers SquibbCopegusRebetolRibavirinVirazole

1 to 9 of 315 results

Back to top